PMC:7386875 / 16850-18196 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T104","span":{"begin":604,"end":612},"obj":"Body_part"},{"id":"T105","span":{"begin":613,"end":622},"obj":"Body_part"},{"id":"T106","span":{"begin":780,"end":788},"obj":"Body_part"},{"id":"T107","span":{"begin":811,"end":819},"obj":"Body_part"},{"id":"T108","span":{"begin":881,"end":902},"obj":"Body_part"},{"id":"T109","span":{"begin":932,"end":937},"obj":"Body_part"},{"id":"T110","span":{"begin":1220,"end":1224},"obj":"Body_part"}],"attributes":[{"id":"A104","pred":"fma_id","subj":"T104","obj":"http://purl.org/sig/ont/fma/fma264783"},{"id":"A105","pred":"fma_id","subj":"T105","obj":"http://purl.org/sig/ont/fma/fma63194"},{"id":"A106","pred":"fma_id","subj":"T106","obj":"http://purl.org/sig/ont/fma/fma264783"},{"id":"A107","pred":"fma_id","subj":"T107","obj":"http://purl.org/sig/ont/fma/fma62851"},{"id":"A108","pred":"fma_id","subj":"T108","obj":"http://purl.org/sig/ont/fma/fma73750"},{"id":"A109","pred":"fma_id","subj":"T109","obj":"http://purl.org/sig/ont/fma/fma68877"},{"id":"A110","pred":"fma_id","subj":"T110","obj":"http://purl.org/sig/ont/fma/fma256135"}],"text":"COVID-19 and Microvascular Thrombosis\nIn addition to macrovascular complications, there is a strong association of COVID-19 with microvascular thrombosis. Pulmonary microvascular thrombosis has been previously described in autopsies as a complication of severe ARDS and has subsequently been reported to complicate ARDS during outbreaks of other coronaviruses, including SARS-CoV and MERS-CoV.36–41 However, this feature appears more pronounced in severe SARS-CoV-2 infection, with histology from patients with COVID-19-associated respiratory failure demonstrating a 9-fold increase in the prevalence of alveolar-capillary microthrombi when compared with patients with influenza.42 In this regard, autopsy findings have shown that, in addition to the expected features of diffuse alveolar damage found in ARDS, platelet-fibrin thrombi are a common microscopic finding in the small pulmonary vasculature, occurring in 80% to 100% of lungs examined at autopsy.43–45 In combination with other reported thrombotic events, the emerging microvascular thrombotic complications indicate a strong interaction between the SARS-CoV-2 and coagulation. Below, we review the underlying known mechanisms for thrombosis and the growing body of work that implicates SARS-CoV-2 as a key player driving many molecular processes underpinning pathological thrombosis."}

LitCovid-PD-UBERON

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T18","span":{"begin":613,"end":622},"obj":"Body_part"},{"id":"T19","span":{"begin":891,"end":902},"obj":"Body_part"}],"attributes":[{"id":"A18","pred":"uberon_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/UBERON_0001982"},{"id":"A19","pred":"uberon_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/UBERON_0002049"}],"text":"COVID-19 and Microvascular Thrombosis\nIn addition to macrovascular complications, there is a strong association of COVID-19 with microvascular thrombosis. Pulmonary microvascular thrombosis has been previously described in autopsies as a complication of severe ARDS and has subsequently been reported to complicate ARDS during outbreaks of other coronaviruses, including SARS-CoV and MERS-CoV.36–41 However, this feature appears more pronounced in severe SARS-CoV-2 infection, with histology from patients with COVID-19-associated respiratory failure demonstrating a 9-fold increase in the prevalence of alveolar-capillary microthrombi when compared with patients with influenza.42 In this regard, autopsy findings have shown that, in addition to the expected features of diffuse alveolar damage found in ARDS, platelet-fibrin thrombi are a common microscopic finding in the small pulmonary vasculature, occurring in 80% to 100% of lungs examined at autopsy.43–45 In combination with other reported thrombotic events, the emerging microvascular thrombotic complications indicate a strong interaction between the SARS-CoV-2 and coagulation. Below, we review the underlying known mechanisms for thrombosis and the growing body of work that implicates SARS-CoV-2 as a key player driving many molecular processes underpinning pathological thrombosis."}

LitCovid-PD-MONDO

LitCovid-PD-CLO

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T129","span":{"begin":91,"end":92},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T130","span":{"begin":190,"end":193},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T131","span":{"begin":236,"end":237},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T132","span":{"begin":270,"end":273},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T133","span":{"begin":393,"end":395},"obj":"http://purl.obolibrary.org/obo/CLO_0001313"},{"id":"T134","span":{"begin":396,"end":398},"obj":"http://purl.obolibrary.org/obo/CLO_0053794"},{"id":"T135","span":{"begin":565,"end":568},"obj":"http://purl.obolibrary.org/obo/CLO_0001618"},{"id":"T136","span":{"begin":565,"end":568},"obj":"http://purl.obolibrary.org/obo/CLO_0001619"},{"id":"T137","span":{"begin":565,"end":568},"obj":"http://purl.obolibrary.org/obo/CLO_0001620"},{"id":"T138","span":{"begin":839,"end":840},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T139","span":{"begin":932,"end":937},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T140","span":{"begin":961,"end":963},"obj":"http://purl.obolibrary.org/obo/CLO_0053799"},{"id":"T141","span":{"begin":1079,"end":1080},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T142","span":{"begin":1263,"end":1264},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"COVID-19 and Microvascular Thrombosis\nIn addition to macrovascular complications, there is a strong association of COVID-19 with microvascular thrombosis. Pulmonary microvascular thrombosis has been previously described in autopsies as a complication of severe ARDS and has subsequently been reported to complicate ARDS during outbreaks of other coronaviruses, including SARS-CoV and MERS-CoV.36–41 However, this feature appears more pronounced in severe SARS-CoV-2 infection, with histology from patients with COVID-19-associated respiratory failure demonstrating a 9-fold increase in the prevalence of alveolar-capillary microthrombi when compared with patients with influenza.42 In this regard, autopsy findings have shown that, in addition to the expected features of diffuse alveolar damage found in ARDS, platelet-fibrin thrombi are a common microscopic finding in the small pulmonary vasculature, occurring in 80% to 100% of lungs examined at autopsy.43–45 In combination with other reported thrombotic events, the emerging microvascular thrombotic complications indicate a strong interaction between the SARS-CoV-2 and coagulation. Below, we review the underlying known mechanisms for thrombosis and the growing body of work that implicates SARS-CoV-2 as a key player driving many molecular processes underpinning pathological thrombosis."}

LitCovid-PD-HP

{"project":"LitCovid-PD-HP","denotations":[{"id":"T35","span":{"begin":448,"end":475},"obj":"Phenotype"},{"id":"T36","span":{"begin":531,"end":550},"obj":"Phenotype"},{"id":"T37","span":{"begin":772,"end":795},"obj":"Phenotype"}],"attributes":[{"id":"A35","pred":"hp_id","subj":"T35","obj":"http://purl.obolibrary.org/obo/HP_0033141"},{"id":"A36","pred":"hp_id","subj":"T36","obj":"http://purl.obolibrary.org/obo/HP_0002878"},{"id":"A37","pred":"hp_id","subj":"T37","obj":"http://purl.obolibrary.org/obo/HP_0033006"}],"text":"COVID-19 and Microvascular Thrombosis\nIn addition to macrovascular complications, there is a strong association of COVID-19 with microvascular thrombosis. Pulmonary microvascular thrombosis has been previously described in autopsies as a complication of severe ARDS and has subsequently been reported to complicate ARDS during outbreaks of other coronaviruses, including SARS-CoV and MERS-CoV.36–41 However, this feature appears more pronounced in severe SARS-CoV-2 infection, with histology from patients with COVID-19-associated respiratory failure demonstrating a 9-fold increase in the prevalence of alveolar-capillary microthrombi when compared with patients with influenza.42 In this regard, autopsy findings have shown that, in addition to the expected features of diffuse alveolar damage found in ARDS, platelet-fibrin thrombi are a common microscopic finding in the small pulmonary vasculature, occurring in 80% to 100% of lungs examined at autopsy.43–45 In combination with other reported thrombotic events, the emerging microvascular thrombotic complications indicate a strong interaction between the SARS-CoV-2 and coagulation. Below, we review the underlying known mechanisms for thrombosis and the growing body of work that implicates SARS-CoV-2 as a key player driving many molecular processes underpinning pathological thrombosis."}

LitCovid-PD-GO-BP

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T37","span":{"begin":1127,"end":1138},"obj":"http://purl.obolibrary.org/obo/GO_0050817"}],"text":"COVID-19 and Microvascular Thrombosis\nIn addition to macrovascular complications, there is a strong association of COVID-19 with microvascular thrombosis. Pulmonary microvascular thrombosis has been previously described in autopsies as a complication of severe ARDS and has subsequently been reported to complicate ARDS during outbreaks of other coronaviruses, including SARS-CoV and MERS-CoV.36–41 However, this feature appears more pronounced in severe SARS-CoV-2 infection, with histology from patients with COVID-19-associated respiratory failure demonstrating a 9-fold increase in the prevalence of alveolar-capillary microthrombi when compared with patients with influenza.42 In this regard, autopsy findings have shown that, in addition to the expected features of diffuse alveolar damage found in ARDS, platelet-fibrin thrombi are a common microscopic finding in the small pulmonary vasculature, occurring in 80% to 100% of lungs examined at autopsy.43–45 In combination with other reported thrombotic events, the emerging microvascular thrombotic complications indicate a strong interaction between the SARS-CoV-2 and coagulation. Below, we review the underlying known mechanisms for thrombosis and the growing body of work that implicates SARS-CoV-2 as a key player driving many molecular processes underpinning pathological thrombosis."}

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T72","span":{"begin":0,"end":37},"obj":"Sentence"},{"id":"T73","span":{"begin":38,"end":154},"obj":"Sentence"},{"id":"T74","span":{"begin":155,"end":1139},"obj":"Sentence"},{"id":"T75","span":{"begin":1140,"end":1346},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"COVID-19 and Microvascular Thrombosis\nIn addition to macrovascular complications, there is a strong association of COVID-19 with microvascular thrombosis. Pulmonary microvascular thrombosis has been previously described in autopsies as a complication of severe ARDS and has subsequently been reported to complicate ARDS during outbreaks of other coronaviruses, including SARS-CoV and MERS-CoV.36–41 However, this feature appears more pronounced in severe SARS-CoV-2 infection, with histology from patients with COVID-19-associated respiratory failure demonstrating a 9-fold increase in the prevalence of alveolar-capillary microthrombi when compared with patients with influenza.42 In this regard, autopsy findings have shown that, in addition to the expected features of diffuse alveolar damage found in ARDS, platelet-fibrin thrombi are a common microscopic finding in the small pulmonary vasculature, occurring in 80% to 100% of lungs examined at autopsy.43–45 In combination with other reported thrombotic events, the emerging microvascular thrombotic complications indicate a strong interaction between the SARS-CoV-2 and coagulation. Below, we review the underlying known mechanisms for thrombosis and the growing body of work that implicates SARS-CoV-2 as a key player driving many molecular processes underpinning pathological thrombosis."}

2_test

{"project":"2_test","denotations":[{"id":"32586214-14660106-21597696","span":{"begin":393,"end":395},"obj":"14660106"},{"id":"32586214-12845623-21597696","span":{"begin":393,"end":395},"obj":"12845623"},{"id":"32586214-15272286-21597696","span":{"begin":393,"end":395},"obj":"15272286"},{"id":"32586214-14506633-21597696","span":{"begin":393,"end":395},"obj":"14506633"},{"id":"32586214-26486634-21597696","span":{"begin":393,"end":395},"obj":"26486634"},{"id":"32586214-6859225-21597696","span":{"begin":393,"end":395},"obj":"6859225"},{"id":"32586214-32294295-21597697","span":{"begin":958,"end":960},"obj":"32294295"}],"text":"COVID-19 and Microvascular Thrombosis\nIn addition to macrovascular complications, there is a strong association of COVID-19 with microvascular thrombosis. Pulmonary microvascular thrombosis has been previously described in autopsies as a complication of severe ARDS and has subsequently been reported to complicate ARDS during outbreaks of other coronaviruses, including SARS-CoV and MERS-CoV.36–41 However, this feature appears more pronounced in severe SARS-CoV-2 infection, with histology from patients with COVID-19-associated respiratory failure demonstrating a 9-fold increase in the prevalence of alveolar-capillary microthrombi when compared with patients with influenza.42 In this regard, autopsy findings have shown that, in addition to the expected features of diffuse alveolar damage found in ARDS, platelet-fibrin thrombi are a common microscopic finding in the small pulmonary vasculature, occurring in 80% to 100% of lungs examined at autopsy.43–45 In combination with other reported thrombotic events, the emerging microvascular thrombotic complications indicate a strong interaction between the SARS-CoV-2 and coagulation. Below, we review the underlying known mechanisms for thrombosis and the growing body of work that implicates SARS-CoV-2 as a key player driving many molecular processes underpinning pathological thrombosis."}

LitCovid-PubTator

PMC:7386875 / 16850-18196 JSONTXT

Annnotations TAB JSON ListView MergeView

PMC:7386875 / 16850-18196 JSON TXT